Medicina Baseada em Evidências
Comentário sobre estudo | História da hipotermia na parada cardíaca, 2002-2021 (RIP).
18 Jun, 2021 | 10:29hA history of hypothermia for cardiac arrest, 2002-2021 (RIP) – PulmCrit
Estudo original: RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
Comentário no Twitter
A history of hypothermia for cardiac arrest, 2002-2021 (RIP)🪦
🥶2002 studies supporting hypothermia were weak
🥶robust studies refute benefit (TTM1 & TTM2)
🥶growing evidence of iatrogenic harm
🥶post-arrest hypothermia should be restricted to within RCTshttps://t.co/GZbpgHXWoD pic.twitter.com/ILUAiqqLQl— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) June 17, 2021
As designações de autoria nos artigos que podem prejudicar as colaborações científicas.
17 Jun, 2021 | 10:52hThe authorship rows that sour scientific collaborations – Nature
Opinião | O futuro da preparação para uma pandemia: coordenação ágil em torno de estudos clínicos.
11 Jun, 2021 | 10:40hThe future of pandemic preparedness: agile coordination around clinical trials – STAT
Perspectiva | Como a COVID mudou a ciência.
9 Jun, 2021 | 09:55hHow COVID Changed Science – Scientific American
Aprovação do FDA para medicamento contra o Alzheimer gera controvérsia entre médicos.
9 Jun, 2021 | 09:49hComunicado de imprensa: FDA Grants Accelerated Approval for Alzheimer’s Drug – U.S. Food & Drug Administration
Comentários: ICER Issues Statement on the FDA’s Approval of Aducanumab for Alzheimer’s Disease – Institute for Clinical and Economic Review E Landmark Alzheimer’s Drug Approval Confounds Research Community – Nature E FDA approves Alzheimer’s drug from Biogen, against experts’ advice – NBC News E F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works – The New York Times (alguns artigos gratuitos por mês) E Alzheimer’s drug approved despite doubts about effectiveness – Science (alguns artigos gratuitos por mês) E The FDA Has Approved A New Alzheimer’s Drug — Here’s Why That’s Controversial – NPR E Opinion: Bad medicine: aducanumab is a lackluster drug with a high price tag – STAT
Opinião | Nova arma das publicações científicas para a próxima crise: correção rápida.
9 Jun, 2021 | 09:45hScientific publishing’s new weapon for the next crisis: the rapid correction – STAT
Editor-chefe do JAMA deixa o cargo após a repercussão de um podcast que questionava o racismo na medicina.
2 Jun, 2021 | 10:17hVer também: JAMA editor in chief steps down over tweet that questioned racism in medicine – MarketWatch E The Editor Of A Top Medical Journal Is Leaving After The Publication Said “No Physician Is Racist” – Buzzfeed News
Editorial do JAMA: To Howard Bauchner, MD, Visionary Editor in Chief of JAMA—A Sincere Thank You and a Fond Farewell
Opinião | A teoria do vazamento da Covid-19 de um laboratório é uma história de incerteza.
31 Mai, 2021 | 12:15hThe Covid-19 Lab Leak Theory Is a Tale of Weaponized Uncertainty – Wired
Ver também: Divisive COVID ‘lab leak’ debate prompts dire warnings from researchers – Nature
Bullying acadêmico é frequentemente ignorado. Estes são alguns relatos dos alvos.
31 Mai, 2021 | 12:02hAcademic bullying is too often ignored. Here are some targets’ stories – Science (poucos artigos gratuitos por mês)
Revisão sistemática: As evidências são insuficientes para determinar os riscos e os benefícios da suplementação de vitamina D como tratamento da COVID-19.
25 Mai, 2021 | 15:52hResumo: Is vitamin D an effective and safe treatment for COVID-19? – Cochrane Library